Literature DB >> 20686031

Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Kathleen C Prins1, Jennifer M Binning, Reed S Shabman, Daisy W Leung, Gaya K Amarasinghe, Christopher F Basler.   

Abstract

The ebolavirus (EBOV) VP35 protein binds to double-stranded RNA (dsRNA), inhibits host alpha/beta interferon (IFN-α/β) production, and is an essential component of the viral polymerase complex. Structural studies of the VP35 C-terminal IFN inhibitory domain (IID) identified specific structural features, including a central basic patch and a hydrophobic pocket, that are important for dsRNA binding and IFN inhibition. Several other conserved basic residues bordering the central basic patch and a separate cluster of basic residues, called the first basic patch, were also identified. Functional analysis of alanine substitution mutants indicates that basic residues outside the central basic patch are not required for dsRNA binding or for IFN inhibition. However, minigenome assays, which assess viral RNA polymerase complex function, identified these other basic residues to be critical for viral RNA synthesis. Of these, a subset located within the first basic patch is important for VP35-nucleoprotein (NP) interaction, as evidenced by the inability of alanine substitution mutants to coimmunoprecipitate with NP. Therefore, first basic patch residues are likely critical for replication complex formation through interactions with NP. Coimmunoprecipitation studies further demonstrate that the VP35 IID is sufficient to interact with NP and that dsRNA can modulate VP35 IID interactions with NP. Other basic residue mutations that disrupt the VP35 polymerase cofactor function do not affect interaction with NP or with the amino terminus of the viral polymerase. Collectively, these results highlight the importance of conserved basic residues from the EBOV VP35 C-terminal IID and validate the VP35 IID as a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686031      PMCID: PMC2950600          DOI: 10.1128/JVI.00925-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

3.  Interactions of Marburg virus nucleocapsid proteins.

Authors:  S Becker; C Rinne; U Hofsäss; H D Klenk; E Mühlberger
Journal:  Virology       Date:  1998-09-30       Impact factor: 3.616

4.  Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes.

Authors:  E Mühlberger; B Lötfering; H D Klenk; S Becker
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

6.  Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Reed S Shabman; Mina Farahbakhsh; Kathleen C Prins; Dominika M Borek; Tianjiao Wang; Elke Mühlberger; Christopher F Basler; Gaya K Amarasinghe
Journal:  J Mol Biol       Date:  2010-04-24       Impact factor: 5.469

7.  A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire.

Authors:  Yannik Boehmann; Sven Enterlein; Anke Randolf; Elke Mühlberger
Journal:  Virology       Date:  2005-02-05       Impact factor: 3.616

8.  Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems.

Authors:  E Mühlberger; M Weik; V E Volchkov; H D Klenk; S Becker
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells.

Authors:  B H Harcourt; A Sanchez; M K Offermann
Journal:  Virology       Date:  1998-12-05       Impact factor: 3.616

10.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  48 in total

1.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

2.  Ebola virus VP35 has novel NTPase and helicase-like activities.

Authors:  Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong; Xi Zhou
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

3.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

4.  RNA Binding of Ebola Virus VP30 Is Essential for Activating Viral Transcription.

Authors:  Nadine Biedenkopf; Julia Schlereth; Arnold Grünweller; Stephan Becker; Roland K Hartmann
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

5.  Ebola Virus Inclusion Body Formation and RNA Synthesis Are Controlled by a Novel Domain of Nucleoprotein Interacting with VP35.

Authors:  Tsuyoshi Miyake; Charlotte M Farley; Benjamin E Neubauer; Thomas P Beddow; Thomas Hoenen; Daniel A Engel
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

6.  Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.

Authors:  Parameshwaran Ramanan; Megan R Edwards; Reed S Shabman; Daisy W Leung; Ariel C Endlich-Frazier; Dominika M Borek; Zbyszek Otwinowski; Gai Liu; Juyoung Huh; Christopher F Basler; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

7.  DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function.

Authors:  Reed S Shabman; Daisy W Leung; Joshua Johnson; Nicole Glennon; Erol E Gulcicek; Kathryn L Stone; Lawrence Leung; Lisa Hensley; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

8.  Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription.

Authors:  Andrey Ivanov; Palaniappan Ramanathan; Christian Parry; Philipp A Ilinykh; Xionghao Lin; Michael Petukhov; Yuri Obukhov; Tatiana Ammosova; Gaya K Amarasinghe; Alexander Bukreyev; Sergei Nekhai
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

9.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

10.  The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Authors:  Ndongala M Lubaki; Philipp Ilinykh; Colette Pietzsch; Bersabeh Tigabu; Alexander N Freiberg; Richard A Koup; Alexander Bukreyev
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.